| Identification | Back Directory | [Name]
GNF-6702 | [CAS]
1799329-72-8 | [Synonyms]
GNF-6702
5-Oxazolecarboxamide, N-[4-fluoro-3-[6-(2-pyridinyl)[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl- | [Molecular Formula]
C22H16FN7O2 | [MDL Number]
MFCD31612571 | [MOL File]
1799329-72-8.mol | [Molecular Weight]
429.41 |
| Hazard Information | Back Directory | [Uses]
GNF6702 is a selective inhibitor of the kinetoplastid proteasome. GNF6702 clears parasites in murine models of leishmaniasis, Chagas disease, and human African trypanosomiasis[1]. | [Definition]
ChEBI: GNF6702 is an aromatic amide obtained by formal condensation of the carboxy group of 2,4-dimethyl-1,3-oxazole-5-carboxylic acid with the aromatic amino group of 4-fluoro-3-[6-(pyridin-2-yl)[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]aniline. A proteasome inhibitor known to be active against the three parasites that cause Chagas disease, leishmaniasis and sleeping sickness. It has a role as a proteasome inhibitor and an antileishmanial agent. It is a member of triazolopyrimidines, a member of pyridines, a member of monofluorobenzenes, a member of 1,3-oxazoles, a ring assembly and an aromatic amide. | [IC 50]
Trypanosoma; Leishmania | [References]
[1] Nagle A, et al. Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases. J Med Chem. 2020;63(19):10773-10781. DOI:10.1021/acs.jmedchem.0c00499 |
|
|